Quantcast

Latest Nycomed Stories

2009-05-06 15:05:00

CUPERTINO, Calif., May 6 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2009. Total revenues were $6.2 million for the three months ended March 31, 2009, compared to $6.4 million for the same period in 2008. Net loss for the three months ended March 31, 2009 was $8.7 million, compared to a net loss of $7.8 million for the same period in 2008. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) At...

2009-05-06 06:00:00

BETHESDA, Md., May 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2009. In the first quarter of 2009, Micromet achieved a number of significant milestones illustrating its continued progress in the clinic and in corporate development. The milestones include the execution...

2009-04-02 06:00:00

BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first clinical trial application (CTA) in Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million Euro (US$ 2.0 million) from Nycomed for the achievement of this milestone. Under a 2007...

2009-03-23 05:00:00

LONDON, March 23 /PRNewswire/ -- The "2008 European Tissue Sealants & Topical Hemostats Product Differentiation Innovation Award" is conferred on Nycomed in recognition of its revolutionary product - TachoSil. The innovative surgical patch, TachoSil is poised to be the future of the European tissue sealants and topical hemostats markets. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) At present, Nycomed, with TachoSil, is the sole company in the market with a ready-to-use...

2008-11-07 09:00:25

MORRIS PLAINS, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $4.9 million and a net loss of $2.2 million, or $0.03 per share, for the first quarter of fiscal year 2009, which ended September 30, 2008. This compares to revenues of $0.8 million and a net loss of $4.6 million, or $0.06 per share, for the same period last year....

2008-10-28 09:00:39

ZURICH, Switzerland, Oct. 28 /PRNewswire/ -- Nycomed today announced encouraging results from a preliminary analysis of four Phase III trials of Daxas(R) (roflumilast) in the treatment of symptomatic COPD. Two pivotal 12-month studies met their primary endpoints, showing effects on exacerbation rates and pulmonary function (FEV1). Furthermore, two supporting six-month studies confirmed the efficacy of Daxas when used with standard bronchodilator treatments. Further analysis including the...

2008-08-28 18:00:51

MORRIS PLAINS, N.J., Aug. 28, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $1.0 million and a net loss of $6.9 million, or $0.09 per share, for the fourth quarter of fiscal year 2008, which ended June 30, 2008. This compares to revenues of $0.8 million and a net loss of $4.6 million, or $0.06 per share, for the same period last year. The...

2008-08-11 09:00:21

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported its recent developments and financial results for the second quarter and six months ended June 30, 2008, and its cash balance as of June 30, 2008. Significant Recently Announced Developments: -- The Reacquisition of Elestrin(TM): BioSante reacquired Elestrin (estradiol gel), U.S. Food and Drug Administration (FDA) approved for the treatment of menopausal hot flashes, from Nycomed US Inc., and will assume all...

2008-08-07 09:00:14

BETHESDA, Md., Aug. 7 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the second quarter and six months ended June 30, 2008. Summary of Recent Events: In June, Micromet and MedImmune presented a clinical update for the BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the International Conference...

2008-07-31 03:00:20

Australia's industry self-regulator Medicines Australia has fined some of the major drug companies over $1.8 million on account of several sales breaches - vilifying rivals' products and lavish spending on educational presentations for doctors. Pfizer Australia was fined $200,000 after it was proved that its representatives in NSW and Queensland misinformed the doctors about a cholesterol-lowering drug produced by rival AstraZeneca. The doctors were told that AstraZeneca's drug may cause...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related